Biomerica’s inFoods® IBS Data Accepted for Presentation at Digestive Disease Week 2026
Rhea-AI Summary
Biomerica (Nasdaq: BMRA) announced that real-world clinical data on its inFoods® IBS diagnostic-guided therapy was accepted for poster presentation at Digestive Disease Week (DDW) 2026, May 2–5 in Chicago.
The poster, presented by investigators from Michigan Medicine and Cleveland Clinic, follows a June 2025 randomized trial in Gastroenterology; DDW embargoed data release begins 12:01 a.m. CDT on the presentation day.
Positive
- Poster accepted for presentation at DDW 2026
- Study presented by Michigan Medicine and Cleveland Clinic investigators
- Builds on a June 2025 randomized trial published in Gastroenterology
Negative
- Study data under DDW embargo until 12:01 a.m. CDT on presentation day
- No numerical efficacy or statistical results disclosed in this announcement
News Market Reaction – BMRA
In the Apr 29 session, BMRA declined 0.92%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 16 | Reimbursement update | Positive | +4.3% | Medicare contractor confirmed inFoods IBS claims review and $300 payment rate. |
| Apr 14 | Product launch | Positive | +1.0% | Launch of inFoods IBS in Canada via distribution and lab partners. |
| Apr 13 | Earnings results | Neutral | +1.0% | Q3 FY2026 results with lower sales but European growth and lower R&D spend. |
| Mar 18 | Commercial order | Positive | +2.9% | First commercial Hp Detect order from major European lab chain. |
| Mar 05 | Regulatory approval | Positive | -3.0% | MHRA registration for hp+detect enabling commercial sales in Great Britain. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent product and reimbursement news for inFoods® IBS and Hp Detect™ has generally seen modest positive price reactions, with one notable divergence on a regulatory approval headline.
Over the past months, Biomerica has advanced commercialization and reimbursement for inFoods® IBS and Hp Detect™ while managing financial strain. Key milestones include MHRA registration for hp+detect™ in Great Britain on Mar 5, 2026, a first commercial Hp Detect™ order in Europe, and Canadian launch of inFoods® IBS. Medicare set a $300 national payment rate and confirmed claim-by-claim review for inFoods® IBS. Against this backdrop of clinical validation and early commercial traction, the DDW 2026 data presentation further supports the inFoods® IBS clinical story.
Key Terms
irritable bowel syndrome medical
gastroenterology medical
hepatology medical
gastrointestinal medical
diagnostic-guided therapy medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Real-world clinical experience with the novel IBS-specific guided diagnostic therapy to be presented at the world’s largest GI medical conference, May 2–5, 2026, in Chicago
IRVINE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global biomedical technology company focused on innovative diagnostic-guided therapies, today announced that an abstract evaluating the real-world clinical effectiveness of its inFoods® IBS diagnostic-guided therapy has been accepted for poster presentation at Digestive Disease Week® (DDW) 2026, to be held May 2–5, 2026, at McCormick Place in Chicago, Illinois.
DDW is the world’s largest gathering of physicians, researchers, and industry professionals in gastroenterology, hepatology, and related GI disciplines. Acceptance of this poster reflects the growing interest within the gastroenterology community in personalized, non-pharmacologic dietary management strategies for patients with irritable bowel syndrome (IBS).
| Novel IBS-specific Guided Elimination Diet Significantly Reduces Abdominal Symptoms in Individuals With IBS: A Real-world Experience Authors: Bill Hirsch, MD (University of Michigan), William D. Chey, MD (University of Michigan), Anthony Lembo, MD (Clevland Clinic), Prashant Singh, MD (University of Michigan) Display Time: May 2, 2026 at 12:30 to 1:30 pm CT, McCormick Place, Chicago, IL |
The real-world study will be presented by investigators from Michigan Medicine (University of Michigan) and Cleveland Clinic. The study builds on findings from a multicenter, double-blinded, placebo-controlled trial of the inFoods® IBS test published in the June 2025 issue of Gastroenterology. Per DDW embargo policy, study data will be made available beginning at 12:01 a.m. CDT on the day of presentation.
ABOUT DIGESTIVE DISEASE WEEK® 2026
Digestive Disease Week® (DDW) is the world’s largest gathering of physicians, researchers, and industry professionals in gastroenterology, hepatology, endoscopy, and gastrointestinal surgery. DDW 2026 will be held May 2–5, 2026, in Chicago, Illinois. Additional information regarding DDW can be found at www.ddw.org.
ABOUT INFOODS® IBS
inFoods® IBS is a diagnostic-guided therapy that identifies patient-specific food triggers responsible for symptoms such as abdominal pain, bloating, diarrhea, and constipation. Using a simple finger-stick blood sample, the test enables physicians to recommend targeted dietary changes tailored to the patient’s immune response—offering a non-pharmaceutical, precision-based approach to symptom relief.
A multicenter, double-blinded sham-controlled trial on the inFoods® IBS test was published in the June 2025 issue of Gastroenterology, a peer-reviewed GI journal. The study demonstrated statistically significant outcomes:
- 59.6% of patients in the treatment group (who eliminated identified trigger foods) achieved the FDA’s endpoint for abdominal pain reduction, compared to
42.1% in the control group.
- Among IBS-C patients,
67.1% of patients in the treatment group vs.35.8% in the control group.
- Among IBS-M patients,
66% of patients in the treatment group vs.29.5% in the control group.
These results highlight the potential effectiveness of a personalized dietary therapy based on inFoods® IBS in IBS patients. The study was conducted at leading U.S. institutions including Cleveland Clinic, Mayo Clinic, and University of Michigan.
ABOUT IRRITABLE BOWEL SYNDROME (IBS)
IBS affects an estimated 30 to 45 million adults in the United States, representing
inFoods® IBS takes a fundamentally different approach—a precision diagnostic that identifies individual food triggers via a simple finger-stick blood test, enabling targeted, patient-specific dietary recommendations. This non-pharmacologic, personalized solution addresses a significant unmet clinical need within an estimated
ABOUT BIOMERICA, INC.
Biomerica, Inc. (www.biomerica.com) is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point of care (in home and in physicians’ offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. The Company’s products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica’s primary focus is on gastrointestinal and inflammatory diseases where the Company has multiple diagnostic and therapeutic products in commercialization.
FORWARD-LOOKING STATEMENTS
The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Certain information included in this press release contains statements that are forward-looking, such as statements relating to the Company’s current and future cash position, balance sheet, revenues, cost of goods, operations, and earnings; the Company’s need for raising additional capital; the Company’s expected sales growth for the inFoods IBS® product, size of the IBS market, Hp Detect product and other existing products; and diversification of the Company’s revenue streams. Such forward-looking information is based upon the current beliefs and expectations of management and involves important risks and uncertainties that could significantly affect anticipated results. In addition, these forward-looking statements are subject to assumptions with respect to future business strategies and decisions that are subject to change. Accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. Factors that could cause actual results to differ from those expressed in the forward-looking statements are discussed in the “Risk Factors” section of the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other reports filed with the SEC, and available on the SEC’s website (www.sec.gov). The Company is under no obligation to update any forward-looking statements after the date of this release.
Corporate Contact
Zack Irani-Cohen
Biomerica, Inc.
949-645-2111 | investors@biomerica.com
www.biomerica.com
